CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -106.44M | -208.55M | -136.00M | -37.31M | -85.94M |
| Total Depreciation and Amortization | 4.43M | 4.65M | 4.74M | 4.84M | 4.74M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.47M | 106.53M | 22.47M | 6.79M | 14.65M |
| Change in Net Operating Assets | 10.91M | -16.51M | 54.85M | -24.35M | -40.36M |
| Cash from Operations | -84.63M | -113.88M | -53.95M | -50.03M | -106.91M |
| Capital Expenditure | -74.00K | -117.00K | -206.00K | -254.00K | -219.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -119.15M | 70.09M | -19.55M | 106.08M | -161.39M |
| Cash from Investing | -119.23M | 69.98M | -19.76M | 105.83M | -161.60M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 296.77M | 2.26M | 10.59M | 16.88M | 9.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 296.77M | 2.26M | 10.59M | 16.88M | 9.64M |
| Foreign Exchange rate Adjustments | -27.00K | 80.00K | 41.00K | -87.00K | 75.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.88M | -41.57M | -63.07M | 72.59M | -258.80M |